EP
RPRX icon

Essential Partners’s Royalty Pharma RPRX Stock Holding History

Essential Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.37K Hold
78
– – ﹤0.01% 1606
2026
Q1 		$3.74K Hold
78
– – ﹤0.01% 1719
2025
Q4 		$3.01K Hold
78
– – ﹤0.01% 1643
2025
Q3 		$2.75K Hold
78
– – ﹤0.01% 1680
2025
Q2 		$2.81K Buy
+78
New +$2.58K ﹤0.01% 1223

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Essential Partners's RPRX Position: Q2 2026 in Review

Essential Partners held its Royalty Pharma (RPRX) position steady in Q2 2026 at 78 shares worth $4.37K. The position accounts for ﹤0.01% of the portfolio, ranked #1606.

Essential Partners first reported a position in RPRX in Q2 2025 and has held it in 5 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Essential Partners held 78 shares of Royalty Pharma worth $4.37K as of Q2 2026.
  • Essential Partners left its Royalty Pharma share count unchanged in Q2 2026.
  • Royalty Pharma made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1606 holding.
  • Essential Partners first reported a position in Royalty Pharma in Q2 2025 and has held it in 5 quarters since.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.